Altimmune

Ask Sterling

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Favorites

Revenue Breakdown

Revenue Flow

Balance Sheet

Q3 2016-Q2 2026

Cash Flow

Q3 2016-Q2 2026

Altimmune

Clinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.

$ALTGaithersburg, MD55altimmune.com

SectorsGLP-1

Frequently asked questions

What does Altimmune do?

Altimmune (ALT) is a Biotechnology company. Clinical-stage biotech. Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers. It was founded in 1997, is headquartered in Gaithersburg, MD and employs about 55 people.

How has Altimmune's revenue and profitability trended?

Track Altimmune's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 21, 2026.

Who are Altimmune's main competitors?

Sterling groups Altimmune in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).

If I'm investing in Altimmune, what similar companies should I consider?

If you are researching Altimmune, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.